tixagevimab + cilgavimab

**Tixagevimab + cilgavimab** is a co-packaged, long-acting combination of two Fc-engineered human IgG1 monoclonal antibodies developed for prevention and treatment of COVID-19. The antibodies bind distinct, non-overlapping epitopes in the receptor-binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral attachment to host-cell ACE2 and thereby preventing viral entry. Both antibodies contain YTE substitutions to extend serum half-life and TM substitutions that reduce Fc receptor and complement binding. The product was marketed as **Evusheld** for COVID-19 pre-exposure prophylaxis, particularly in people unlikely to mount an adequate vaccine response; however, loss of activity against later viral variants led to loss of U.S. authorization and withdrawal of the European Union marketing authorization. ([nejm.org](https://www.nejm.org/doi/pdf/10.1056/NEJMoa2116620))

Brand names

Evusheld

Other names

cilgavimab + tixagevimabtixagevimab + cilgavimabtixagevimab co-packaged with cilgavimabtixagevimab-cilgavimabtixagevimab/cilgavimab